Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Study DB2116961, a multicentre, randomised, blinded, parallel group study to compare UMEC/VI (Umeclidinium/Vilanterol) in a fixed dose combination with Indacaterol plus Tiotropium in symptomatic subjects with moderate to very severe COPD

Next Previous
Search
Trial Profile

Study DB2116961, a multicentre, randomised, blinded, parallel group study to compare UMEC/VI (Umeclidinium/Vilanterol) in a fixed dose combination with Indacaterol plus Tiotropium in symptomatic subjects with moderate to very severe COPD

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 28 Jun 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Umeclidinium/vilanterol (Primary) ; Indacaterol; Tiotropium bromide
  • Indications Chronic obstructive pulmonary disease
  • Focus Registrational; Therapeutic Use
  • Sponsors GlaxoSmithKline; GlaxoSmithKline Research & Development; GSK

    • Most Recent Events

    • 30 Jun 2019 Trial has been completed in Romania, according to European Clinical Trials Database record.
    • 30 Mar 2016 Primary endpoint has been met. (Change From Baseline in Trough Forced Expiratory Volume in One Second (FEV1) on Treatment Day 85 (Visit 8)) as per the results published in the Drugs in R and D.
    • 30 Mar 2016 Results published in the Drugs in R and D

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top